Authors

Latest:

Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

Do-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).

Angela J. Keleher, MD, FACS

Latest:

Let’s Talk About Post-Mastectomy Chest Numbness

Just as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.

J. Nicholas Bodor, MD, PhD, MPH

Latest:

Dr Bodor on a Study Profiling Estrogen Species in Women With EGFR-Mutated NSCLC

J. Nicholas Bodor, MD, PhD, MPH, discusses the results of prior research supporting the inception of a study that profiled reactive estrogen species in women with EGFR-positive non–small cell lung cancer, as well as the findings from this study.

Winship Cancer Institute

Latest:

The American Cancer Society, Winship Partner to Accelerate Cancer Research in Georgia

The American Cancer Society, in partnership with Winship Cancer Institute of Emory University, announced a new project that aims to significantly accelerate cancer research and improve patient outcomes.

Aditya Bardia, MD, Massachusetts General Hospital Cancer Center

Latest:

Future Directions for the Management of HR+ Breast Cancer

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

Justine Kahn, MD, MS

Latest:

Dr. Kahn on the Importance of Diverse Clinical Trial Participation in Oncology

Justine Kahn, MD, MS, discusses the importance of diverse clinical trial participation within the oncology space.

Ryotaro Nakamura, MD, City of Hope

Latest:

Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Dan Pollyea, MD, MS

Latest:

Dr. Pollyea on the Role of Maintenance Therapy in AML

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

Michael Shusterman, MD

Latest:

Dr Shusterman on a DNA Methylome Enrichment Platform for Early Detection of Solid Tumors

Michael Shusterman, MD, discusses findings from a retrospective study to determine the feasibility of a novel genome-wide methylome enrichment platform for the early detection of multiple solid tumors.

Mariana X. Byndloss, DVM, PhD

Latest:

Dr Byndloss on the Relationship Between the Gut Microbiome and GI Cancers

Mariana X. Byndloss, DVM, PhD, discusses how the gut microbiome influences human health, highlighting the relationship between the gut microbiome and a person’s risk for developing gastrointestinal cancers, as well as characteristics of a healthy gut microbiome.

Rutgers Cancer Institute

Latest:

Expert Commentary: Insights into Cancer Mutation Patterns

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

Raji Shameem, MD

Raji Shameem, MD is a medical oncologist and hematologist at Orlando Health Cancer Institute.

Latest:

Dr Shameem on Selecting NALIRIFOX vs FOLFIRINOX in Advanced Pancreatic Cancer

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.

Alexander van Akkooi, MD, PhD, FRACS

Latest:

Dr Akkooi on Pathologic Review Discrepancies and Overtreatment Risks in Metastatic Melanoma

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

Courtney Coschi, MD, PhD

Latest:

Is War a Good Metaphor for Cancer Care?

The National Cancer Act of 1971 introduced the concept of a “war on cancer,” which has since affected the language we use when discussing the disease.

Jarushka Naidoo, MD, M.B.B.Ch.

Latest:

Combination Chemotherapy and Immunotherapy for Advanced NSCLC

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

Sumanta K. Pal, MD

Latest:

Dr Pal on the Rationale for Evaluating Atezolizumab in High-Risk Localized RCC

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Louis Williams, MD

Latest:

Emerging Bispecifics and Trispecifics and Addressing Unmet Needs in R/R MM

Panelists discuss how trispecific antibodies targeting multiple antigens show promise for preventing antigen escape, while identifying ultrahigh-risk patients, frail patients, optimal treatment duration, and therapy access as key unmet needs.

Jiye Liu, PhD

Latest:

Dr Liu on Epigenetic Regulation of CD38/CD48 in Multiple Myeloma

Jiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.

Reena Salgia, MD, Henry Ford Health System

Latest:

Hepatocellular Carcinoma: Practical Implications of Emerging Data

Mehmet K. Samur, PhD

Latest:

Dr. Samur on the Evolving Treatment Landscape in Multiple Myeloma

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.